New hope for hepatitis d: experimental drug enters final testing phase
Disease control
Not yet recruiting
This Phase 3 trial tests a drug called hepalatide (L47) in 150 people with chronic hepatitis D, a serious liver disease. Participants receive either the drug or a placebo daily for 48 weeks. The goal is to see if hepalatide can lower virus levels and normalize liver enzymes. Afte…
Phase: PHASE3 • Sponsor: Shanghai HEP Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC